Background: Hepatic steatosis, a common condition associated with insulin resistance and excess body
Introduction
Hepatic steatosis is a pathological process characterized by an abnormal deposition of fat within the liver, estimated to occur in a third of the Western adult population. 1, 2 It may progress to steatohepatitis and ultimately cirrhosis, conditions which make up a spectrum of hepatic pathologies encompassed by the umbrella term 'non-alcoholic fatty liver disease' . 3, 4 Within the general population, steatosis is most commonly associated with a high body mass index (BMI) and insulin resistance. 3, 5 The diagnosis is conventionally made histologically, when Ն5% of liver tissue is seen to contain fat. 4, 5 As the presence of steatosis mirrors the presence of excess body adiposity, and the latter is an established risk factor for incident cancer, 6 including colorectal cancer, 7 it is reasonable to hypothesize that steatosis is an adverse factor for outcome after resection of colorectal liver metastases (CLM).
In patients undergoing resection of CLM, background liver steatosis may additionally be caused by preoperative chemotherapy (notably irinotecan-containing regimens), 8, 9 in which the histological appearance is similar to that in excess body adiposity. Steatosis is a relatively common finding in liver resection specimens, although rates vary from 18% to 56% depending on the diagnostic criteria used, [10] [11] [12] and several reports have described an association with increased risk for perioperative morbidity, particularly in patients undergoing a major liver resection 11, [13] [14] [15] (removal of three or more segments according to the Brisbane 2000 Terminology of Liver Anatomy and Resections 16 ). A recent meta-analysis 17 concluded that moderate/severe steatosis (Ն30%) was associated with an increased risk for perioperative mortality, but apart from the study by Behrns et al. 13 (published at a time when it was uncommon to administer preoperative chemotherapy), all the studies in this analysis 17 grouped together patients with steatosis regardless of whether they had or had not received preoperative chemotherapy. 11, 14, 15, 17 If the confounding effects of preoperative chemotherapy are not taken into account, it is unclear whether obesity-related steatosis per se impacts adversely on early outcome. In terms of longterm survival, to date only three studies have evaluated the impact of steatosis or steatohepatitis. One of these included cancer types other than CLM; 14 the other two were small but limited to CLM and reported non-significant reductions in, respectively, median overall survival (OS) in patients with steatosis, 12 and median recurrence-free survival in patients with severe grade steatohepatitis. 18 As with studies of early outcome, these studies of longterm outcome did not take account of the confounding effects of preoperative chemotherapy.
This study aimed to use data from the international registry, LiverMetSurvey, to assess the effect of background liver steatosis on perioperative and longterm survival in patients undergoing resection of CLM. To control for the confounding effects of chemotherapy, and to assess survival in relation to that in steatosis arising from obesity-related causes, the analysis was limited to patients who did not receive preoperative chemotherapy.
Materials and methods

Database
LiverMetSurvey (http://www.livermetsurvey.org) is a prospective international database of patients with metastatic colorectal cancer undergoing surgery for CLM that comprises data voluntarily registered by 235 centres across 63 countries (many centres started data collection in the early 1990s). [19] [20] [21] The register was developed both to prospectively collect essential clinical data on a multi-institution basis and to evaluate clinical outcome and prognostic factors on a large scale. Data concerning patient demographics, the primary tumour, the number, size and location(s) of liver metastases, the type of hepatic resection, postoperative complications, the time and nature of recurrence, and survival are entered into a register, using a standardized questionnaire that is completed online.
Histological categorization
The local clinical team documents whether background liver histology was normal or abnormal. If it was abnormal, the team completes a tick-box list to indicate whether this abnormality reflected 'congestion' , 'fibrosis' , 'nodular regenerative hyperplasia' , 'steatosis' or 'other' . More than one box may be ticked and free text can be used to describe 'other' pathology. Guidance on how to classify abnormal liver histology is not provided and thus classification methods rely on the local pathology reporting system.
For the purposes of this analysis, background liver histology was classified into three categories: 'normal'; 'steatosis' , and 'other' (hepatic pathologies other than steatosis, such as 'congestion' , 'fibrosis' , 'nodular regenerative hyperplasia'). Combinations of more than one pathology category were re-allocated so that any patients categorized with combined pathologies were allocated to the steatosis category. For example, cases of 'steatosis + fibrosis' or free-text documentation of 'steatohepatitis' were placed in the 'steatosis' category; free-text phrases such as 'sinusoidal obstruction syndrome' and 'vascular' were re-coded as 'congestion' and placed in the 'other' category.
Analysis inclusion
The primary focus of the analysis was patients undergoing firsttime resection with information on background liver histology. The following patients were excluded: those with incomplete chemotherapy data; non-surgical patients; patients undergoing repeat resections (as it was felt that such patients would have an abnormal liver pathology because of regeneration and/or would have received numerous previous cycles of chemotherapy); patients without background liver histology, and patients entered as undergoing first surgery before 1990. To address potential confounding caused by chemotherapy-induced liver injury, the variable 'preoperative chemotherapy' was used to identify a group of patients free from liver-directed chemotherapy. Although not conventionally regarded as a risk factor for chemotherapy-induced liver injury, the 'chemotherapy post-colectomy' variable was used to address the possible confounding effect of adjuvant bowel chemotherapy delivered prior to liver resection.
Follow-up
Data recorded on the 'latest news' page were extracted to ascertain follow-up. Individual follow-up data are inputted sequentially to document whether a patient is alive or not, and if the patient is not alive, whether his or her death was cancer-related.
Statistical analysis
The primary outcome measures in this analysis were: 90-day perioperative mortality (chosen because traditional 30-day mortality does not capture patients in whom death from postoperative liver failure occurs outside this time limit 9, 22 ); OS, and cancer-specific survival (CSS).
Differences in baseline characteristics across the background liver histology categories were explored using standard approaches for continuous (Kruskal-Wallis test) and categorical (chi-squared test for multiple categories) variables as appropriate. Perioperative mortality was expressed using crude rates. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from comparative tests using logistic regression models with adjustments for age, gender and year. These models were extended to test for interactions between steatosis and extent of resection as multiplicative products. The Cochran-Armitage test was used to test for trends across ordered groups (e.g. time periods).
Kaplan-Meier curves were constructed for all time-to-event outcome measures and compared across groups with the standard log-rank test. Time zero was defined as the date of liver resection surgery. Overall survival was defined as the time from first resection to death from any cause, and CSS was defined as time from first resection to death from colorectal cancer. 23 Cox models were applied to assess whether steatosis was an independent prognostic factor on OS and CSS. A seven-step approach advocated by Hosmer and colleagues 24 was used to force background histology categories into the final model. Predictive accuracy and the calibration of the models were tested using a concordance index (C-statistic; values range from 0.5 to 1.0).
To test for confounding, covariates shown to independently prognosticate for survival after resection for CLM according to Rees and colleagues 25 were used. These included: node positive primary; more than three hepatic metastases; carcinoembryonic (CEA) antigen level >60 ng/ml; tumour diameter of Ն5 cm; positive resection margin, and extrahepatic disease. This model was chosen because six of the seven factors were available (information on the differentiation of the primary tumour was not available) and the patients reported by Rees et al. 25 were operated on over a time period comparable with that of the LiverMetSurvey. To take account of multiple testing, a P-value of <0.01 was considered to indicate statistical significance. All statistical analyses were performed using stata Version 11.1 (StataCorp LP, College Station, TX, USA).
Results
Overview
The LiverMetSurvey database included 16 779 procedure cases to December 2011. From these, 5853 patients who underwent first liver resections without preoperative chemotherapy from 1990 were identified. A flow diagram is shown in Fig. 1 . Table 1 shows the baseline characteristics of the cohort for analysis, categorized by pathological background as 'normal' , 'with steatosis' and 'other' . The median age was 64.1 years (interquartile range: 56-71 years) and the male : female ratio was approximately 3.5:2.0. The proportion of patients undergoing resection with background steatosis was 30.6%; this increased from 27.2% during 1990-1995 to 31.3% during 2006-2011, but this difference fell short of statistical significance. Approximately equal numbers of patients underwent minor and major resections. According to the prognostic system described by Rees et al., 25 steatosis was more common in the presence of the following factors: more than three hepatic metastases (P < 0.0001); minimum margin of <1 mm (P = 0.007), and absence of extrahepatic disease (P = 0.003). Additionally, steatosis was more commonly associated with metachronous than synchronous resections (P < 0.001).
Baseline characteristics
Perioperative mortality A total of 160 deaths occurred within 90 days of first resection, giving a crude mortality rate of 2.8% ( Without preoperative chemotherapy n = 5853
Background liver histology
Incomplete chemotherapy data, n = 32
Non-surgical, n = 1092
Background histology unknown, n = 3503
Repeat hepatectomy, n = 1736
Resection pre-1990, n = 234
Preoperative chemotherapy, n = 4329
Normal: n = 3522 (60.2%) Steatosis: n = 1793 (30.6%)
Other pathologies: n = 538 (9.2%) Figure 1 Flow diagram illustrating the selection of the study cohort from patients listed in the LiverMetSurvey database from 1990 to December 2011 );). In general, a higher rate of perimortality occurred in patients undergoing major resections.
To explore this further and take account of differences in age between background liver histology categories, logistic regression models were generated and ORs derived. For all resections, the occurrence of perioperative mortality did not increase in association with steatosis, but did so significantly in association with 'other' pathologies (OR = 1.880, 95% CI 1.204-2.037; P = 0.005). Stratification by extent of surgery did not materially influence these findings and the test for interaction between steatosis and extent of surgery was borderline significant (P = 0.039).
Longterm survival
Median follow-up in the entire cohort was 20 months. The 5-year OS rate was 44.0% (95% CI 42.0-46.0) and 5-year CSS was 51.8% (95% CI 49.7-54.0). By background liver histology, 5-year OS rates in the 'normal' , 'steatosis' and 'other' groups were 43.0%, 47.4% and 39.0%, respectively (Fig. 2a) . The improvement in OS in patients with steatosis compared with normal pathology was significant (log rank test, P = 0.0017). Rates of 5-year CSS in patients with 'normal' , 'steatosis' and 'other' pathologies were 50.3%, 56.1% and 47.2%, respectively (Fig. 2b) . Again, the improvement in CSS in patients with steatosis compared with normal pathologies was significant (log rank test, P = 0.002).
Cox models were used to test whether the improved CSS observed with steatosis reflected confounding ( 25 In this model, the survival reduction associated with steatosis remained materially unchanged (HR = 0.806, 95% CI 0.717-0.905).
Internal validation
The robustness of the finding of a reductive effect of steatosis on CSS was tested further using Cox models stratified by age and year bands (Table 4) . Hazard ratios were similar across these strata, except for the >75 years age band. Additional subsamples taken without replacement, in three sets, derived similar HR estimates for steatosis.
Post-colectomy chemotherapy
Finally, the effect of previous adjuvant post-colectomy chemotherapy as a potential confounder was tested. A total of 2728 (46.6%) patients had received adjuvant chemotherapy prior to liver resection as part of their treatment for primary colorectal cancer; most patients had been given fluoropyrimidine-based therapies. The risk estimate of steatosis on CSS after liver resection was uninfluenced by the addition of whether or not adjuvant chemotherapy had been administered prior to resection (HR = 0.833, 95% CI 0.742-0.936). In a sub-cohort of patients who had received adjuvant chemotherapy for primary colorectal cancer prior to liver resection and for whom complete data on the dates of treatment were available (n = 1594), the test for interaction between presence of steatosis and timing of adjuvant chemotherapy (>6 months versus <6 months prior to resection) was non-significant (P = 0.754).
Discussion
Main findings
This analysis of a large international clinical database showed that, in patients undergoing resection of CLM, without preoperative chemotherapy, steatosis in the background liver occurs in approximately a third of cases. The presence of steatosis in this setting was associated with no increase in perioperative mortality. By contrast, steatosis -assumed here to reflect excess body adiposity -was associated with improved longterm OS and CSS, an observation which remained robust after adjustment for wellestablished prognostic factors. As a secondary finding, patients with other types of liver pathology, including fibrosis, congestion and regenerative nodular hyperplasia, were found to be at high risk for perioperative mortality and worse longterm survival.
Comparison with the published literature
This is the largest analysis to date to evaluate the impact of background steatosis on short-and longterm survival. By contrast with a meta-analysis performed by de Meijer et al., 17 a four-study analysis of 1000 patients which found a 2.5-fold increase in perioperative mortality associated with steatosis of Ն30%, the present study found no such association. There may be several reasons for these differences, including: (i) the de Meijer et al. meta-analysis 17 included a mixture of chemotherapy-treated and chemotherapynaïve patients 11, [13] [14] [15] (steatosis may have divergent effects on early outcomes in these two settings); (ii) the present study defined perioperative mortality as death within 90 days of surgery, whereas the definitions used in studies included in the metaanalysis 17 varied from death within 30 days, 13 to death within 60 days or in-hospital mortality, 14 death within 90 days 15 and death before discharge; 11 (iii) the LiverMetSurvey registry does not consistently grade steatosis, whereas the de Meijer et al. meta- 17 found significant differences in rates of perioperative mortality in the context of steatosis of Ն30%, but not in the more common setting of milder grades of steatosis, and (iv) perioperative mortality after liver resection for CLM is relatively rare: the deaths reported in the small-sample studies included in the metaanalysis by de Meijer et al. 17 may have occurred by chance, whereas the sample size in the present analysis includes more than five times as many patients (5853 versus 1000) and three times as many perioperative deaths (160 versus 49).
Other than one article, which was published in an era in which it was uncommon to administer chemotherapy prior to resection, 13 previous studies have regarded steatosis and steatohepatitis after preoperative chemotherapy as equivalent to those seen in patients who are chemotherapy-naïve. 9, 11, 12, 15, 17 Although druginduced steatosis is indistinguishable on postoperative histology from that seen in individuals who are obese or insulin-resistant, the strong association between this liver injury pattern and irinotecan-based chemotherapy reported previously 8, 9 implies that separate pathological processes may be involved. There is a need to learn more about how an individual's metabolic risk interacts with chemotherapy agents administered preoperatively.
The observation of a survival advantage associated with steatosis in the present analysis is paradoxical. This is set against the findings of three previous studies (Table 5) , which evaluated either steatosis or steatohepatitis in this context and reported findings of a general (albeit non-significant) trend towards reduced survival. However, these studies, the largest of which included only 485 patients 14 (compared with 5853 in the present series), pooled data for chemotherapy-treated and chemotherapynaïve patients and were probably underpowered. The observations derived in the present analysis are perhaps not very surprising when they are considered alongside the findings of other studies that have evaluated the impact of peri-diagnosis obesity, which, in turn, is correlated with steatosis and longterm survival.
Clinical implications
In the general population, liver fat deposition is strongly correlated with visceral obesity and insulin resistance. 5, 26, 27 The paradoxical survival advantage observed in patients in the present analysis generates a hypothesis that peri-diagnosis excess body adiposity provides a survival protective effect that warrants further research. Although it is conventional to view obesity (particularly visceral obesity) as an adverse factor at the diagnosis of several diseases, 28 for cancer, evidence to the contrary is starting to emerge. In their analysis of body composition and outcome in patients undergoing resection of CLM, van Vledder and colleagues 29 found that visceral fat area had no effect on longterm survival, whereas data from the CAIRO trial of chemotherapy in Table 3 Cox proportional hazard model testing the impact of steatosis on cancer-specific survival, with adjustments for prognostic factors according to Rees et al. 25 
Covariates
Hazard ratio 95% CI patients with metastatic colorectal cancer showed improved OS in obese patients compared with those of normal weight. 30 (The authors of the latter study hypothesized that this outcome may have reflected a superior nutritional reserve in obese patients. 30 ) It is too early to conclude that peri-diagnosis obesity is a good prognosticator in metastatic colorectal cancer, but the issue warrants further research.
Strengths and limitations
There are several strengths to this study and analysis. Firstly, the large size of the overall database allowed the analysis to be restricted to patients undergoing first-time liver resection without preoperative chemotherapy, while maintaining an adequate sample size. Secondly, the database captured many wellestablished prognostic factors and the potential confounding of adjuvant post-colectomy chemotherapy; these were included in the Cox model, which showed the main findings to be materially unaffected. Thirdly, the internal validity of the data (e.g. consistency of ages and steatosis diagnoses per year) were tested and no major deviations in parameters were found. Finally, fixed (by year and age groups) and random sampling of three subgroups of the main dataset were used and produced similar results.
This study has limitations. Firstly, a clinical database such as that of the LiverMetSurvey is reliant upon the accuracy of data entry. For example, pathology reporting is not standardized across LiverMetSurvey centres and, in particular, the 5% cut-off value used to make a diagnosis of steatosis 4 has not subsequently been applied with consistency in the wider literature. 11, 15 Steatosis was captured as either present or absent, which prevented further analysis according to grade or the presence of steatohepatitis. Nonetheless, when steatosis is assessed using visual techniques, it may be more appropriate to refer simply to its presence or absence because considerable inter-rater variability for steatosis grade exists even between expert pathologists (kappa scores: 0.64-0.79). 4 Biochemical and digital counting techniques generate much more precise and reproducible results.
31,32 Secondly, LiverMetSurvey lacks data on BMI, diabetes, alcohol consumption history, and comorbidities (e.g. performance status or anaesthetic assessment scores) and it would have been useful to examine how these correlated with the presence or absence of steatosis and to have investigated whether excess BMI or the presence of diabetes impacted upon survival.
Unanswered questions and future research
The key unanswered question concerns whether or not there is unmeasured residual confounding: examples suggested already include BMI and other anthropometric measurements, metabolic measurements and alcohol consumption, but extend to unmeasured factors that may have favoured certain treatments (i.e. confounding by indication). Other residual confounding may include as yet unmeasured allelic polymorphisms that interact with steatosis and disease progression. The present findings should be replicated in other settings. Examples may include observational analyses within large trials with standardized treatment protocols (thus reducing confounding by indication). In parallel with establishing the true clinical relationships, there is a need to consider biological mechanisms, which are currently very much understudied in humans in terms of the fatty liver-tumour interface. Given the projected increase in the numbers of patients eligible for resection of CLM in the future, 33 and a parallel increase in the prevalence of steatosis in Western populations, better understanding of this topic is likely to benefit many patients. 
